Drug profile · INN
lenvatinib
LENVIMA
lenvatinib (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Associated with Eisai Co.,.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01XE29
Patents linked 0
Pipeline programs 28
News articles 0
Drug details — lenvatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 28
- Data quality
- 0.83
Quick answer
lenvatinib (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Associated with Eisai Co.,.
Key facts
INN lenvatinib
Brand LENVIMA
Mechanism Vascular endothelial growth factor receptor inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XE29
Originator Eisai Co.,
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lenvatinib?
lenvatinib (LENVIMA) is a vascular endothelial growth factor receptor inhibitor. Associated with Eisai Co.,.
What is the brand name for lenvatinib?
LENVIMA is a marketed brand name for lenvatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.